Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
Open Access
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (2) , 393-394
Abstract
Few predictive factors for efficacy of vascular endothelial growth factor pathway-targeted therapies have been identified. We studied whether bevacizumab treatment-related hypertension is associated with outcome. Forty-three consecutive patients with metastatic progressive renal cell cancer (RCC), of whom 41 had cytokine-refractory disease, were treated with bevacizumab [administered either 5 mg/kg every 2 weeks (n = 37) or 7.5 mg/kg every 3 weeks (n = 6)] from June 2004 to March 2007 in our hospital. We used this dose since it was widely used in the treatment of colorectal cancer at the time when RCC patients were accrued [1]. Blood pressure was measured before each bevacizumab infusion and antihypertensive medication was initiated or intensified whenever blood pressure was >150/100 mmHg.Keywords
This publication has 5 references indexed in Scilit:
- Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)Journal of Clinical Oncology, 2008
- Randomized Trials in Oncology Stopped Early for BenefitJournal of Clinical Oncology, 2008
- Hypertension as a predictive factor of Sunitinib activityAnnals of Oncology, 2007
- Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G)Journal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004